Subject
FDA & Regulation: Research Articles for US Labs
Reading on where research peptides stand under US federal law: the Federal Food, Drug, and Cosmetic Act, how far the Controlled Substances Act reaches, the July 2026 compounding advisory committee vote and what it leaves unchanged. Statements point to the FDA or Federal Register document behind them.
- articles
- 5
- sources cited
- 28
- last revised
- Sep 3
Recently Published
Jump to the full library ↓503A vs 503B vs RUO: The Three US Peptide Supply Chains, Compared
Two channels make drugs for patients and one sells chemicals to laboratories, and the rules, the oversight and the quality obligations differ accordingly
Adam Reeves · Sep 3, 2026 · 5 min read · 5 sources
- 02What "Research Use Only" Actually Means in the US After the 2026 FDA Warning LettersFDA & Regulation · Sep 1, 2026 · 4 min
- 03The July 2026 FDA PCAC Peptide Vote: What It Does and Doesn't Change for US ResearchersFDA & Regulation · Aug 30, 2026 · 6 min
- 04FDA's April 2026 Category 2 Removals Explained: 12 Peptides, Zero ApprovalsFDA & Regulation · Aug 28, 2026 · 5 min
The Full Library
FDA Status
5- Regulation
Are Peptides Legal in the US? A Plain-Language Overview
One statute does most of the work, "research use only" is a legal description rather than a disclaimer, and the July 2026 advisory vote changed less than it appeared to
- Regulation
The July 2026 FDA PCAC Peptide Vote: What It Does and Doesn't Change for US Researchers
Six of seven peptides won a non-binding recommendation for the 503A compounding list; for a laboratory buying research reagents, almost nothing moved
- Regulation
FDA's April 2026 Category 2 Removals Explained: 12 Peptides, Zero Approvals
Twelve peptides left the FDA's "do not compound" category because their nominations were withdrawn, which is a procedural change rather than a safety finding or a permission
- Regulation
What "Research Use Only" Actually Means in the US After the 2026 FDA Warning Letters
A label is one piece of evidence about intended use, and the March 2026 warning letters show the FDA reading the rest of the page
- Regulation
503A vs 503B vs RUO: The Three US Peptide Supply Chains, Compared
Two channels make drugs for patients and one sells chemicals to laboratories, and the rules, the oversight and the quality obligations differ accordingly
Other Subjects
Each subject has its own page listing every article filed under it.
- Compound Profiles One peptide per article: the published studies, the gaps in them, and the certificate on file.29
- Comparisons & Bench Methods Paired compounds weighed on the literature, plus reconstitution arithmetic and storage conditions.9
- Verification & Lab Data Checking a certificate yourself: HPLC purity, fill quantity, lab confirmation, doctored reports.8
Who Writes These
Adam Reeves
Research Editor, Eppix Labs
Writes the compound profiles, the certificate-checking guides and the FDA reading in this library. The profile page sets out the scope of the role and lists every article under the byline.
View profile and articles →Editorial Rules
- Where an article summarizes published studies, claims carry a bracketed number that resolves to a References entry with a PubMed ID or a link to the source document.
- Where an article shows a certificate, it is drawn from the lab-results library with its batch number, rather than retyped into the text.
- Each article carries a named byline and the date it was first published.
- Statements about FDA status point to the agency or Federal Register document behind them.
- Laboratory research reference only. No dosing, administration or human-use guidance appears anywhere in the library.
Get the Research Digest
Periodic research summaries and new references, sent to the research list only.
Sold for in vitro laboratory research only. Not a drug, supplement or FDA-approved product, and not for human or veterinary use.